Selenium, Genetic Variation in Selenoenzymes and Prostate Cancer

Cancer Prevention Program

Selenium, Genetic Variation in Selenoenzymes and Prostate Cancer

PI: Ulrike Peters, PhD

The goal of this study is to better understand the molecular and genetic pathways underlying selenium as a chemopreventive agent for prostate cancer. Selenium as an essential element is required for the activity of selenoenzymes, which have important antioxidative properties that prevent oxidative damage to DNA and other biomolecules. Furthermore, selenoenzymes may also modulate inflammation and immune response, and thus may be important for the prevention of prostate cancer.

Within the Prostate Cancer Prevention Trial (PCPT), a large randomized trial, we test whether common genetic variation in selenoenzymes and lifestyle factors are associated with activity of selenoenzymes. Furthermore, we explore biomarkers of oxidative stress, inflammation, and immune response in relation to selenium levels and selenoenzyme activity. We hope to gain a better understanding of the potential chemopreventive effect of selenium on prostate cancer and help to identify men who benefit most from selenium supplementation.

For questions or additional information please contact:

Ulrike Peters, PhD MPH
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N., M4-B402
P.O. Box 19024
Seattle, WA 98109-1024
Phone: (206) 667-2450
Email address: